• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

第二代蛋白酶体抑制剂伊沙佐米在治疗多发性骨髓瘤中的潜力。

The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma.

作者信息

Brayer Jason, Baz Rachid

机构信息

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.

出版信息

Ther Adv Hematol. 2017 Jul;8(7):209-220. doi: 10.1177/2040620717710171. Epub 2017 Jun 28.

DOI:10.1177/2040620717710171
PMID:28694935
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5495505/
Abstract

The therapeutic armamentarium for multiple myeloma has recently benefited from the addition of several new agents (including second-generation proteasome inhibitors, monoclonal antibodies and histone deacetylase inhibitors). This review will focus on ixazomib, an orally bioavailable second-generation proteasome inhibitor. Specifically, we will review the preclinical data, clinical trial experience, potential indications as well as unanswered questions pertaining to this new agent in multiple myeloma.

摘要

多发性骨髓瘤的治疗手段最近受益于多种新药物的加入（包括第二代蛋白酶体抑制剂、单克隆抗体和组蛋白脱乙酰酶抑制剂）。本综述将聚焦于伊沙佐米，一种口服生物利用度高的第二代蛋白酶体抑制剂。具体而言，我们将综述其临床前数据、临床试验经验、潜在适应症以及与这种多发性骨髓瘤新药物相关的未解决问题。

相似文献

1
The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma.第二代蛋白酶体抑制剂伊沙佐米在治疗多发性骨髓瘤中的潜力。
Ther Adv Hematol. 2017 Jul;8(7):209-220. doi: 10.1177/2040620717710171. Epub 2017 Jun 28.
2
An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma.基于证据的来那度胺联合伊沙佐米和硼替佐米治疗初治多发性骨髓瘤的研究进展
Onco Targets Ther. 2014 Sep 29;7:1793-800. doi: 10.2147/OTT.S49187. eCollection 2014.
3
The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor.MUK8 方案：一项随机 II 期临床试验，评估环磷酰胺和地塞米松联合伊沙佐米治疗来那度胺、(lenalidomide)和蛋白酶体抑制剂治疗后复发的复发/难治性多发性骨髓瘤（RRMM）患者的疗效。
Trials. 2020 Oct 2;21(1):826. doi: 10.1186/s13063-020-04739-8.
4
The proteasome and proteasome inhibitors in multiple myeloma.多发性骨髓瘤中的蛋白酶体和蛋白酶体抑制剂。
Cancer Metastasis Rev. 2017 Dec;36(4):561-584. doi: 10.1007/s10555-017-9707-8.
5
Ixazomib for the treatment of multiple myeloma.伊沙佐米治疗多发性骨髓瘤。
Expert Opin Pharmacother. 2018 Dec;19(17):1949-1968. doi: 10.1080/14656566.2018.1528229. Epub 2018 Nov 13.
6
Ixazomib for the treatment of multiple myeloma.伊沙佐米用于治疗多发性骨髓瘤。
Expert Opin Investig Drugs. 2015;24(9):1287-98. doi: 10.1517/13543784.2015.1065250. Epub 2015 Jul 3.
7
Proteasome inhibitors.蛋白酶体抑制剂。
Biochem Pharmacol. 2015 Jul 1;96(1):1-9. doi: 10.1016/j.bcp.2015.04.008. Epub 2015 Apr 29.
8
Safety of proteasome inhibitors for treatment of multiple myeloma.蛋白酶体抑制剂治疗多发性骨髓瘤的安全性。
Expert Opin Drug Saf. 2017 Feb;16(2):167-183. doi: 10.1080/14740338.2017.1259310. Epub 2016 Nov 28.
9
Proteasome inhibitors for multiple myeloma.用于多发性骨髓瘤的蛋白酶体抑制剂
Jpn J Clin Oncol. 2018 Sep 1;48(9):785-793. doi: 10.1093/jjco/hyy108.
10
The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.用于治疗多发性骨髓瘤的研究性蛋白酶体抑制剂伊沙佐米。
Future Oncol. 2015;11(8):1153-68. doi: 10.2217/fon.15.9.

引用本文的文献

1
In vivo activity of the second-generation proteasome inhibitor ixazomib against pediatric T-cell acute lymphoblastic leukemia xenografts.第二代蛋白酶体抑制剂伊沙佐米对儿童T细胞急性淋巴细胞白血病异种移植瘤的体内活性
Exp Hematol. 2024 Apr;132:104176. doi: 10.1016/j.exphem.2024.104176. Epub 2024 Feb 5.
2
Proteomic Alteration in the Progression of Multiple Myeloma: A Comprehensive Review.多发性骨髓瘤进展中的蛋白质组学改变：综述
Diagnostics (Basel). 2023 Jul 10;13(14):2328. doi: 10.3390/diagnostics13142328.
3
Stem Cell Mobilization with Ixazomib and G-CSF in Patients with Multiple Myeloma.伊沙佐米与粒细胞集落刺激因子联合用于多发性骨髓瘤患者的干细胞动员
Cancers (Basel). 2023 Jan 9;15(2):430. doi: 10.3390/cancers15020430.
4
Bone-Targeted Bortezomib Inhibits Bortezomib-Resistant Multiple Myeloma in Mice by Providing Higher Levels of Bortezomib in Bone.骨靶向硼替佐米通过在骨骼中提供更高水平的硼替佐米来抑制小鼠体内对硼替佐米耐药的多发性骨髓瘤。
J Bone Miner Res. 2022 Apr;37(4):629-642. doi: 10.1002/jbmr.4496. Epub 2022 Jan 22.
5
Cell-Based Optimization of Covalent Reversible Ketoamide Inhibitors Bridging the Unprimed to the Primed Site of the Proteasome β5 Subunit.基于细胞的共价可逆酮酰胺抑制剂的优化，该抑制剂桥接连接未修饰的蛋白酶体β5 亚基和修饰的蛋白酶体β5 亚基。
ChemMedChem. 2019 Dec 4;14(23):2005-2022. doi: 10.1002/cmdc.201900472. Epub 2019 Nov 12.
6
Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas.成熟B细胞非霍奇金淋巴瘤靶向药物概述
Front Oncol. 2019 Jun 4;9:443. doi: 10.3389/fonc.2019.00443. eCollection 2019.
7
New proteasome inhibitors in the treatment of multiple myeloma.用于治疗多发性骨髓瘤的新型蛋白酶体抑制剂
Hematol Transfus Cell Ther. 2019 Jan-Mar;41(1):76-83. doi: 10.1016/j.htct.2018.07.003. Epub 2018 Oct 15.
8
Ixazomib promotes CHOP-dependent DR5 induction and apoptosis in colorectal cancer cells.依沙佐米促进结直肠癌细胞中 CHOP 依赖性 DR5 诱导和凋亡。
Cancer Biol Ther. 2019;20(3):284-294. doi: 10.1080/15384047.2018.1529095. Epub 2018 Oct 25.
9
Induction of multiple myeloma cancer stem cell apoptosis using conjugated anti-ABCG2 antibody with epirubicin-loaded microbubbles.用载有表阿霉素的微泡偶联的抗 ABCG2 抗体诱导多发性骨髓瘤肿瘤干细胞凋亡。
Stem Cell Res Ther. 2018 May 21;9(1):144. doi: 10.1186/s13287-018-0885-2.
10
Ixazomib, an oral proteasome inhibitor, induces rapid mobilization of hematopoietic progenitor cells in mice.伊沙佐米是一种口服蛋白酶体抑制剂，可促使小鼠造血祖细胞快速动员。
Blood. 2018 Jun 7;131(23):2594-2596. doi: 10.1182/blood-2017-10-811620. Epub 2018 Apr 25.

本文引用的文献

1
Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial.硼替佐米和沙利度胺维持治疗多发性骨髓瘤患者自体干细胞移植后：一项 PETHEMA/GEM 试验。
Leukemia. 2017 Sep;31(9):1922-1927. doi: 10.1038/leu.2017.35. Epub 2017 Jan 23.
2
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.达雷妥尤单抗、来那度胺和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2016 Oct 6;375(14):1319-1331. doi: 10.1056/NEJMoa1607751.
3
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.达雷妥尤单抗、硼替佐米和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2016 Aug 25;375(8):754-66. doi: 10.1056/NEJMoa1606038.
4
CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.CHAMPION-1：一项关于每周一次卡非佐米和地塞米松治疗复发或难治性多发性骨髓瘤的1/2期研究。
Blood. 2016 Jun 30;127(26):3360-8. doi: 10.1182/blood-2015-11-683854. Epub 2016 May 12.
5
Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and/or t(4;14) and overcomes their adverse prognosis.基于硼替佐米的诱导治疗可改善伴有17p缺失和/或t(4;14)的骨髓瘤患者的无进展生存期，并克服其不良预后。
Ann Hematol. 2016 Aug;95(8):1315-21. doi: 10.1007/s00277-016-2692-0. Epub 2016 May 16.
6
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.来那度胺、伊沙佐米和地塞米松联合治疗多发性骨髓瘤。
N Engl J Med. 2016 Apr 28;374(17):1621-34. doi: 10.1056/NEJMoa1516282.
7
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM.随机2期研究：埃罗妥珠单抗联合硼替佐米/地塞米松对比硼替佐米/地塞米松用于复发/难治性多发性骨髓瘤
Blood. 2016 Jun 9;127(23):2833-40. doi: 10.1182/blood-2016-01-694604. Epub 2016 Apr 18.
8
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.卡非佐米和地塞米松与硼替佐米和地塞米松治疗复发或难治性多发性骨髓瘤患者的比较（ENDEAVOR）：一项随机、3 期、开放标签、多中心研究。
Lancet Oncol. 2016 Jan;17(1):27-38. doi: 10.1016/S1470-2045(15)00464-7. Epub 2015 Dec 5.
9
Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study.伊沙佐米联合来那度胺-地塞米松治疗亚洲复发/难治性骨髓瘤患者的药代动力学及安全性：一项1期研究
J Hematol Oncol. 2015 Sep 4;8:103. doi: 10.1186/s13045-015-0198-1.
10
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.Daratumumab 单药治疗多发性骨髓瘤中针对 CD38。
N Engl J Med. 2015 Sep 24;373(13):1207-19. doi: 10.1056/NEJMoa1506348. Epub 2015 Aug 26.